concept

DOPAMINERGIC

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DOPAMINERGIC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1118Connections

2Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

DOPAMINERGIC is a concept in neurodegeneration research. Key relationships include: co discussed, causes, regulates. Associated with NEURODEGENERATION, PARKINSON, PARKINSON'S. Connected to 145 entities in the SciDEX knowledge graph.

View on Wiki →

💡 Concept Info

Name	DOPAMINERGIC
Summary	Companies developing continuous delivery systems for Parkinson's disease dopaminergic therapy
Key Genes/Proteins	PARKIN
Related Diseases	NEURODEGENERATION, PARKINSON, PARKINSON'S
Linked Hypotheses	3 hypotheses

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    DOPAMINERGIC["<b>DOPAMINERGIC</b>"]
    DOPAMINERGIC -->|"causes"| NEURON["NEURON"]
    DOPAMINERGIC -->|"causes"| NEURONS["NEURONS"]
    DOPAMINERGIC -->|"causes"| SENESCENCE["SENESCENCE"]
    DOPAMINERGIC -->|"causes"| PARKIN["PARKIN"]
    DOPAMINERGIC -->|"causes"| PARKINSON["PARKINSON"]
    DOPAMINERGIC -->|"causes"| PARKINSON_S["PARKINSON'S"]
    DOPAMINERGIC -->|"causes"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
    DOPAMINERGIC -->|"causes"| SUBSTANTIA_NIGRA["SUBSTANTIA NIGRA"]
    DOPAMINERGIC -->|"regulates"| PI3K["PI3K"]
    AKT["AKT"] -->|"regulates"| DOPAMINERGIC
    ASTROCYTE["ASTROCYTE"] -->|"interacts"| DOPAMINERGIC
    ASTROCYTES["ASTROCYTES"] -->|"interacts"| DOPAMINERGIC
    COMPLEMENT["COMPLEMENT"] -->|"activates"| DOPAMINERGIC
    APOPTOSIS["APOPTOSIS"] -->|"causes"| DOPAMINERGIC
    AMPK["AMPK"] -->|"activates"| DOPAMINERGIC
    AUTOPHAGY["AUTOPHAGY"] -->|"promotes"| DOPAMINERGIC

Outgoing (273)

Target	Relation	Type	Str
NEURODEGENERATION	mediates	disease	0.65
NEURON	expressed_in	cell_type	0.65
NEURONS	expressed_in	cell_type	0.65
PARKIN	biomarker_for	gene	0.65
PARKINSON	biomarker_for	disease	0.65
PARKINSON'S	biomarker_for	disease	0.65
GLUTAMATERGIC	causes	cell_type	0.65
NEURONS	inhibits	cell_type	0.65
NEURODEGENERATION	associated_with	disease	0.65
MICROGLIA	inhibits	cell_type	0.65
NEURON	reduces	cell_type	0.65
NEURONS	reduces	cell_type	0.65
STRIATUM	reduces	brain_region	0.65
SUBSTANTIA NIGRA	reduces	brain_region	0.65
NEURODEGENERATION	accumulates_in	disease	0.65
NEURON	treats	cell_type	0.65
NEURONS	treats	cell_type	0.65
IBA1	associated_with	gene	0.65
TNF-ALPHA	regulates	gene	0.65
NEURON	biomarker_for	cell_type	0.65
NEURONS	biomarker_for	cell_type	0.65
NEURON	contributes_to	cell_type	0.65
NEURON	accumulates_in	cell_type	0.65
PARKIN	accumulates_in	gene	0.65
PARKINSON	accumulates_in	disease	0.65
PARKINSON'S	accumulates_in	disease	0.65
PARKINSON'S DISEASE	accumulates_in	disease	0.65
GABAERGIC	regulates	cell_type	0.65
SUBSTANTIA NIGRA	accumulates_in	brain_region	0.65
SUBSTANTIA NIGRA	associated_with	brain_region	0.65
NEURONS	accumulates_in	cell_type	0.65
PARKIN	reduces	gene	0.65
PARKINSON	reduces	disease	0.65
PARKINSON'S	reduces	disease	0.65
PARKINSON'S DISEASE	reduces	disease	0.65
MICROGLIA	increases	cell_type	0.65
RAPAMYCIN	regulates	drug	0.65
NEURON	phosphorylates	cell_type	0.65
NEURONS	phosphorylates	cell_type	0.65
PARKIN	phosphorylates	gene	0.65
TAU	mediates	gene	0.65
PREFRONTAL CORTEX	causes	brain_region	0.65
STING	expressed_in	gene	0.65
TH	expressed_in	gene	0.65
FYN	inhibits	gene	0.65
PARKIN	treats	gene	0.65
PARKINSON	treats	disease	0.65
SYNUCLEINOPATHY	causes	disease	0.65
NEURON	causes	cell_type	0.60
NEURONS	causes	cell_type	0.60

Incoming (845)

Source	Relation	Type	Str
AIF1	associated_with	gene	0.65
ATG5	associated_with	gene	0.65
ATG7	associated_with	gene	0.65
BECN1	associated_with	gene	0.65
CASP1	associated_with	gene	0.65
AQP4	causes	gene	0.65
AKT	regulates	gene	0.60
ASTROCYTE	interacts_with	cell_type	0.60
ASTROCYTES	interacts_with	cell_type	0.60
AMPK	activates	gene	0.60
CORTEX	causes	brain_region	0.60
DEPRESSION	contributes_to	disease	0.60
DEPRESSION	causes	disease	0.60
AKT	co_discussed	entity	0.50
AUTOPHAGY	co_discussed	entity	0.50
BECN1	co_discussed	entity	0.50
CASP1	co_discussed	entity	0.50
CYTOKINE	co_discussed	entity	0.50
ASTROCYTE	co_discussed	entity	0.50
ASTROCYTES	co_discussed	entity	0.50
CORTEX	co_discussed	entity	0.50
COMPLEMENT	co_discussed	entity	0.50
APOPTOSIS	co_discussed	entity	0.50
CIRCADIAN	co_discussed	entity	0.50
ALPHA-SYNUCLEIN	co_discussed	entity	0.50
AMPK	co_discussed	entity	0.50
MITOCHONDRIA	associated_with	cell_type	0.50
NEURONS	associated_with	concept	0.50
Neuron	causes	cell_type	0.50
NEURONS	causes	concept	0.50
PARKINSON	protects_against	gene	0.50
Parkinson's Disease	protects_against	disease	0.50
Neuron	protects_against	cell_type	0.50
disease	protects_against	disease	0.50
NEURONS	protects_against	concept	0.50
Substantia Nigra	protects_against	entity	0.50
PARKINSON'S	protects_against	concept	0.50
Neuron	associated_with	cell_type	0.50
Pi3K	regulates	pathway	0.50
CELL CYCLE	regulates	cell_type	0.50
SYNAPSE	regulates	concept	0.50
Neurodegeneration	associated_with	disease	0.50
RGS6	associated_with	gene	0.50
PARKINSON	activates	gene	0.50
Parkinson's Disease	activates	disease	0.50
disease	activates	disease	0.50
PARKINSON'S	activates	concept	0.50
PSAP	interacts_with	gene	0.50
Neuron	interacts_with	cell_type	0.50
NEURONS	interacts_with	concept	0.50

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio	0.494	neuroscience	Circuit-level neural dynamics in neurode
Correcting Gut Microbial Dopamine Imbalance to Support Syste	0.412	neurodegeneration	What are the mechanisms by which gut mic

Mentioning Analyses (2)

Scientific analyses that reference this entity

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

neurodegeneration | 2026-04-13 | 0 hypotheses

What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.467

Related Papers (10)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Striatal Dysregulation of Angpt2 and Circadian Gene Expression in a Rotenone Rat [PMID:41925987]	Al Saeedy DY, Hawkins E, Dozmorov MG, Tr	J Mol Neurosci	2026
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders [PMID:41699128]	["Bolsewig K", "Bellomo G", "Hok-A-Hin Y	Nature medicine	2026
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertain [PMID:41562409]	Benina N, Buitrago L, De Simone FI, Radw	Brain	2026
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by [PMID:39881147]	["Bolsewig K", "Willemse E", "S\u00e1nch	Nature communications	2025
Characterization of Vps13b-mutant mice reveals neuroanatomical and behavioral ph [PMID:37573958]	["Montillot C", "Skutunova E", "Ayushma"	Neurobiology of disease	2023
Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neu [PMID:36692274]	["Motta C", "Assogna M", "Bonomi C", "Di	European journal of neurology	2023
Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal car [PMID:33547425]	Lieberwirth JK, Joset P, Heinze A, Hents	European journal of human gene	2021
Environmental Regulation, Technological Innovation, and Export Competitiveness: [PMID:32102174]	Liu J, Xie J	International journal of envir	2020
Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables. [PMID:33442582]	Karas M, Marinsek N, Goldhahn J, Foschin	Digital biomarkers	2020
DOPA Decarboxylase Modulates Tau Toxicity. [PMID:28751068]	["Kow R", "Sikkema C", "Wheeler J", "Wil	Biological psychiatry	2018

DOPAMINERGIC

Understanding Entity Pages

Summary

Wiki Pages (21)

Continuous Dopaminergic Stimulation for Parkinson's Disease

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

Parthanatos in Neurodegeneration

CBS/PSP Rehabilitation Master Guide

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

NPM1 Gene

PI-2620 Tau PET in PSP